Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic

By A. Puri, Kristin H. Loomis, Brandon Smith, Jae-Ho Lee, Amichai Yavlovich, Eli Heldman, R. Blumenthal. Critical reviews in therapeutic drug carrier systems, 2009

864 citations recorded by the source corpus.

In recent years, various nanotechnology platforms in the area of medical biology, including both diagnostics and therapy, have gained remarkable attention. Moreover, research and development of engineered multifunctional nanoparticles as pharmaceutical drug carriers have spurred exponential growth in applications to medicine in the last decade. Design principles of these nanoparticles, including nano-emulsions, dendrimers, nano-gold, liposomes, drug-carrier conjugates, antibody-drug complexes, and magnetic nanoparticles, are primarily based on unique assemblies of synthetic, natural, or biological components, including but not limited to synthetic polymers, metal ions, oils, and lipids as their building blocks. However, the potential success of these particles in the clinic relies on consideration of important parameters such as nanoparticle fabrication strategies, their physical properties, drug loading efficiencies, drug release potential, and, most importantly, minimum toxicity of the carrier itself. Among these, lipid-based nanoparticles bear the advantage of being the least toxic for in vivo applications, and significant progress has been made in the area of DNA/RNA and drug delivery using lipid-based nanoassemblies. In this review, we will primarily focus on the recent advances and updates on lipid-based nanoparticles for their projected applications in drug delivery. We begin with a review of current activities in the field of liposomes (the so-called honorary nanoparticles), and challenging issues of targeting and triggering will be discussed in detail. We will further describe nanoparticles derived from a novel class of amphipathic lipids called bolaamphiphiles with unique lipid assembly features that have been recently examined as drug/DNA delivery vehicles. Finally, an overview of an emerging novel class of particles (based on lipid components other than phospholipids), solid lipid nanoparticles and nanostructured lipid carriers will be presented. We conclude with a few examples of clinically successful formulations of currently available lipid-based nanoparticles.

Subfields: Molecular Biology, Pharmaceutical Science

View Paper: https://www.semanticscholar.org/paper/4ffce91615eed5995d45ec1d3d26f2bd7ea61a72

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pharmaceutical Science

Citations in the corpus

Strategies to Address Low Drug Solubility in Discovery and Development (2013, background): “…liposomes: Lian and Ho (2001), Constantinides et al. (2008), and Puri et al. (2009); and the following reviews are recommended for solid lipid nanoparticles: Müller et al. (2000), Mehnert and Mader (2001), Wissing et al. (2004), Joshi and Muller (2009), Puri et al. (2009), and Bunjes (2010).”
Improving emulsion formation, stability and performance using mixed emulsifiers: A review. (2017, background): “Oil-in-water emulsions are important constituents of many commercial products, including foods, supplements, pharmaceuticals, cosmetics, personal care products, and agrochemicals [1-3].”
Cancer nanomedicine: a review of recent success in drug delivery (2017, methodology): “Common lab methods used to create liposomal nanoparticles include sonication, extrusion, reversephase evaporation, and solvent injection [52].”
Advances and Challenges of Liposome Assisted Drug Delivery (2015, background): “A number of studies have demonstrated enhanced uptake and efficacy of ligand-targeted liposomes in diseased tissue in comparison to non-targeted liposomes in vivo (Vingerhoeds et al., 1994; Puri et al., 2009; Allen and Cullis, 2013; Kraft et al., 2014).”
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, background): “to be determined and will likely depend on characteristics of the molecular target (e.g., expression, location, internalization rate and immunogenicity; Puri et al., 2009; Hua and Wu, 2013; Kraft et al., 2014).”